Related Experiment Video

Updated: Aug 8, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

[Drug development in paediatric oncology]

G Benninger-Döring1, J Boos

  • 1Universitätsklinikum Münster, Klinik und Poliklinik für Kinder- und Jugendmedizin, Pädiatrische Hämatologie/Onkologie, Münster.

Klinische Padiatrie
|May 12, 2006
PubMed

Insights

Pediatric cancer cure rates are high, but many drugs are used off-label. Pre-clinical screening and networking can accelerate drug development for children, reducing off-label use.

Area of Science:

  • Pediatric Oncology
  • Drug Development
  • Clinical Trials

Context:

  • Over 75% cure rates in childhood cancer are achieved today.
  • However, 60-90% of drugs used in pediatric oncology are prescribed off-label.
  • This highlights a significant gap in targeted pediatric drug availability.

Purpose:

  • To explore strategies for improving drug selection and development for pediatric cancer.
  • To leverage upcoming EU regulations and foster collaboration among research institutions.
  • To reduce the incidence of off-label drug use in treating childhood cancers.

Summary:

  • Comprehensive pre-clinical screening of drug candidates can create prioritized lists for pediatric use.
  • New EU regulations and increased networking among institutions can boost pediatric clinical trials.
  • Establishing robust networks can attract pharmaceutical partnerships, aiming to decrease off-label prescribing.

Impact:

  • Accelerated development of targeted therapies for pediatric cancer patients.
  • Enhanced collaboration between research societies, trial groups, and the pharmaceutical industry.
  • Significant reduction in off-label medication use, improving treatment safety and efficacy for children with cancer.

More Related Videos

A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells06:32

A Neonatal Intravenous Transplant Model for Assessment of Early-Life Immune Activities Against Cancer Cells

Published on: June 26, 2026

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...